Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study

Canadian Family Physician

Volumn 53, Issue 3, 2007, Pages 409-412

  Chambers, Christina ^a   Koren, Gideon ^b   Tutuncu, Zuhre N ^a   Johnson, Diana ^a   Jones, Kenneth L ^a  

^a California Terratogen Information Service   (United States)

^b Motherisk Program   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CHLOROQUINE; CYCLOSPORIN; ETANERCEPT; FOLIC ACID ANTAGONIST; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE;

ABORTION; CONGENITAL MALFORMATION; DRUG SAFETY; FALLOT TETRALOGY; HUMAN; INTESTINE MALROTATION; INTRAUTERINE GROWTH RETARDATION; LOW DRUG DOSE; MALARIA; NEURAL TUBE DEFECT; NONHUMAN; PREGNANCY; PREGNANCY OUTCOME; PREMATURITY; PRENATAL DRUG EXPOSURE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ABNORMALITIES, DRUG-INDUCED; ANTIMALARIALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AZATHIOPRINE; FEMALE; HUMANS; INCIDENCE; INFORMATION SERVICES; ISOXAZOLES; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; RISK ASSESSMENT; SULFASALAZINE; TERATOGENS;

EID: 34047207613     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Nielsen OH, Andreasson B, Bondesen S, Jarnum S. Pregnancy in ulcerative colitis. Scand J Gastroenterol l983;18:735-42.
2. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists in pregnancy. Am J Epidemiol 2001;153(10):961-8.
3. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 2003;30:241-6.
4. Levy M, Buskila D, Gladman DD, Koren G. Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol l991;8(3):174-8.
5. Buchanan NM, Toubi E, Khamashta MA, Lima F, Kerslake S, Hughes GR. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis l996;55(7):486-8.
6. Parke AL, West B. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol l996;23:1715-8.
7. Klinger G, Morad Y, Westall CA, Laskin C, Spitzer KA, Koren G, et al. Ocular toxicity and antenatal exposure to chloroquine and hydroxychloroquine for rheumatic diseases. Lancet 2001;358:813-4.
8. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004;99(12):2385-92.
9. Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005;21(6):733-8.
10. Orozco C, Dao K, Cush JJ, Kavanaugh A. Safety of TNF-inhibitors during pregnancy in patients with inflammatory arthritis [abstract]. Arthritis Rheum 2005;52(9 Suppl):22-3.
11. Herold M, Schnohr S, Bittrish H. Efficacy and safety of a combined rituximab chemotherapy during pregnancy [abstract]. J Clin Oncol 2001;19(14):3439.
12. Kimby E, Sverrisdottir A, Elinder G. Safety of rutiximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol 2004;72:292-5.